CSIMarket Company Name, Ticker, Industry, else..


Vericel Corporation  (NASDAQ: VCEL)
Other Ticker:  
 

Vericel Corporation

VCEL's Fundamental analysis



Looking into Vericel growth rates, revenue grew by 15.97 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 906

Biotechnology & Pharmaceuticals industry recorded deterioration of revenues by -2.61 %

Vericel's net income grew by 52.44 % in IV. Quarter 2024 year on year, above company average,

• More on VCEL's Growth


Vericel
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Vericel PEG ratio is at -1.59 Vericel realized cash reduction of $ -0.04 per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
391.25
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 10.1.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.55.


• More on VCEL's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 847,229
 Net Income/Employee (TTM) $ 37,007
 Receivable Turnover (TTM) 4.57
 Tangible Book Value (Per Share $) 5.51

Vericel
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Vericel PEG ratio is at -1.59 Vericel realized cash outflow of $ -0.04per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
391.25
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 10.1.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.55.

Vericel Price to Book Ratio is at 8.21 lower than Industry Avg. of 1411.8. and higher than S&P 500 Avg. of 0.01

• More on VCEL's Valuation

•  Market Capitalization (Millions $) 2,397
•  Shares Outstanding (Millions) 52
•  Employees 280
•  Revenues (TTM) (Millions $) 237
•  Net Income (TTM) (Millions $) 10
•  Cash Flow (TTM) (Millions $) -2
•  Capital Exp. (TTM) (Millions $) -64
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 847,229
•  Net Income/Employee(TTM) $ 37,007
•  Receivable Turnover Ratio (TTM) 4.57
•  Tangible Book Value (Per Share $) 5.51

•  Market Capitalization (Millions $) 2,397
•  Shares Outstanding (Millions) 52
•  Employees 280
•  Revenues (TTM) (Millions $) 237
•  Net Income (TTM) (Millions $) 10
•  Cash Flow (TTM) (Millions $) -2
•  Capital Exp. (TTM) (Millions $) -64


    VCEL's Profitability Comparisons
Vericel achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in IV. Quarter 2024 to 24.52 %.

Vericel net profit margin of 26.28 % is currently ranking no. 8 in Biotechnology & Pharmaceuticals industry, ranking no. 40 in Healthcare sector and number 485 in S&P 500.


Profitability by Segment
Total 4.37 %



  Ratio
•   Capital Ratio (MRQ) 4.23
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.49
•  Asset Turnover Ratio (TTM) 0.75
•  Inventory Turnover Ratio (TTM) 4.23



Vericel achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in IV. Quarter 2024 to 24.52 %.

Vericel net profit margin of 26.28 % is currently ranking no. 8 in Biotechnology & Pharmaceuticals industry, ranking no. 40 in Healthcare sector and number 485 in S&P 500.

• More on VCEL's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com